Lab
Associated Pathologists LLC
Associated Pathologists LLC was paid $27.79M by Medicaid between Jan 2018 and Dec 2024, across 114 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 20% of everything it billed.
33Billing provider infoASSOCIATED PATHOLOGISTS LLC
NASHVILLE, TN 37217
NASHVILLE, TN 37217
33aNPI1124075635assigned 05/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$27.79M
24GClaims1,275,915
24DCodes billed114
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#4 of 70
Median peer was paid$141K
This provider vs. median197×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WALKER, MATTHEW controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,959 | $1.41M | |
| 2019 | 91,202 | $1.47M | |
| 2020 | 107,974 | $2.66M | |
| 2021 | 246,761 | $6.37M | |
| 2022 | 277,175 | $6.22M | |
| 2023 | 276,522 | $5.96M | |
| 2024incomplete | 194,322 | $3.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 20% | 93,798 | 87,077 | $5.69M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.9% | 116,034 | 110,347 | $2.47M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.8% | 114,560 | 108,943 | $2.44M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 8.0% | 107,337 | 102,418 | $2.23M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 6.3% | 38,151 | 36,664 | $1.76M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 5.4% | 87,008 | 84,353 | $1.49M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 4.3% | 68,992 | 19,146 | $1.20M |
| 87481 | 4.0% | 76,571 | 36,801 | $1.12M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.8% | 19,231 | 17,112 | $1.06M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.3% | 5,406 | 5,160 | $915K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.3% | 48,307 | 45,304 | $913K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 3.0% | 3,662 | 3,447 | $841K |
102 more codes
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.0% | 39,885 | $823K |
| 87653 | 2.9% | 36,960 | $795K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 2.8% | 2,748 | $774K |
| 87511 | 1.5% | 25,274 | $410K | |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 273,335 | $403K |
| 88307 | 1.3% | 3,076 | $358K | |
| 87529 | 1.1% | 13,059 | $315K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,406 | $261K |
| 88185 | <1% | 576 | $155K | |
| 87625 | <1% | 6,421 | $139K | |
| 88141 | <1% | 10,790 | $136K | |
| 88342 | <1% | 2,968 | $118K | |
| 88341 | <1% | 1,344 | $110K | |
| 88312 | <1% | 2,115 | $89K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,994 | $86K |
| 88304 | <1% | 3,084 | $81K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,129 | $80K |
| 81513 | <1% | 879 | $63K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,316 | $61K |
| 88142 | <1% | 3,939 | $57K | |
| 88374 | <1% | 241 | $55K | |
| 81329 | <1% | 1,423 | $35K | |
| 87563 | <1% | 2,175 | $27K | |
| 88189 | <1% | 438 | $21K | |
| 87536 | <1% | 489 | $19K | |
| 88112 | <1% | 629 | $19K | |
| 83020 | <1% | 3,089 | $18K | |
| 88184 | <1% | 513 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,170 | $16K |
| 87902 | <1% | 139 | $14K | |
| 88302 | <1% | 747 | $14K | |
| 87640 | <1% | 565 | $12K | |
| 81511 | <1% | 2,860 | $12K | |
| 88360 | <1% | 156 | $8K | |
| 88313 | <1% | 90 | $8K | |
| 87493 | <1% | 207 | $6K | |
| 87510 | <1% | 515 | $6K | |
| 87480 | <1% | 489 | $6K | |
| 88275 | <1% | 82 | $6K | |
| 87660 | <1% | 432 | $5K | |
| 81422 | <1% | 1,236 | $4K | |
| 87521 | Neg quan hep c or qual rna | <1% | 136 | $4K |
| 88311 | <1% | 248 | $2K | |
| 88271 | <1% | 82 | $2K | |
| 88291 | <1% | 114 | $1K | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 134 | $878.79 |
| 81243 | <1% | 20 | $872.16 | |
| 81241 | <1% | 78 | $840.95 | |
| 84165 | <1% | 211 | $818.28 | |
| 85060 | <1% | 41 | $509.38 | |
| 88280 | <1% | 31 | $484.57 | |
| 88300 | <1% | 13 | $134.43 | |
| 81219 | <1% | 27 | $110.68 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,020 | $70.32 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 125 | $29.51 |
| 81001 | <1% | 1,955 | $7.90 | |
| 87210 | 0% | 247 | $0.00 | |
| 85007 | 0% | 20 | $0.00 | |
| 85610 | 0% | 1,075 | $0.00 | |
| 0761T | 0% | 395 | $0.00 | |
| 0753T | 0% | 3,851 | $0.00 | |
| 0752T | 0% | 470 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 569 | $0.00 |
| 81003 | 0% | 745 | $0.00 | |
| 86900 | 0% | 283 | $0.00 | |
| 84100 | 0% | 795 | $0.00 | |
| 81269 | 0% | 54 | $0.00 | |
| 87186 | 0% | 446 | $0.00 | |
| 85049 | 0% | 38 | $0.00 | |
| 0760T | 0% | 653 | $0.00 | |
| 84702 | 0% | 74 | $0.00 | |
| 85380 | 0% | 67 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 24 | $0.00 |
| 83690 | 0% | 1,273 | $0.00 | |
| 84132 | 0% | 203 | $0.00 | |
| 80320 | 0% | 888 | $0.00 | |
| 82330 | 0% | 882 | $0.00 | |
| 85730 | 0% | 638 | $0.00 | |
| 82803 | 0% | 533 | $0.00 | |
| 83605 | 0% | 1,219 | $0.00 | |
| 80053 | Comprehensive metabolic panel | 0% | 3,044 | $0.00 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 702 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 3,738 | $0.00 |
| 80329 | 0% | 985 | $0.00 | |
| 84484 | 0% | 1,604 | $0.00 | |
| 85027 | 0% | 6,209 | $0.00 | |
| 83735 | 0% | 971 | $0.00 | |
| 87070 | 0% | 837 | $0.00 | |
| 84703 | 0% | 1,776 | $0.00 | |
| 87077 | 0% | 270 | $0.00 | |
| 0756T | 0% | 106 | $0.00 | |
| 86901 | 0% | 143 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 198 | $0.00 |
| 87040 | 0% | 866 | $0.00 | |
| 0754T | 0% | 1,277 | $0.00 | |
| 86850 | 0% | 90 | $0.00 | |
| 0751T | 0% | 156 | $0.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 42 | $0.00 |
| 81596 | 0% | 13 | $0.00 | |
| 83880 | 0% | 92 | $0.00 | |
| 87205 | 0% | 21 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 58 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALKER, MATTHEW (SVP, REVENUE CYCLE MANAGEMENT)
| Provider | Location | Paid |
|---|---|---|
| Pathgroup Labs, LLC | Nashville, TN | $62.07M |
| Associated Pathologists, LLC | Nashville, TN | $61.42M |
| Village Caregiving, LLC | Barboursville, WV | $16.75M |
| William Bee Ririe Hospital | Ely, NV | $7.24M |
| William Bee Ririe Hospital | Ely, NV | $2.35M |
| Matthew E. Walker PC INC | Tahlequah, OK | $1.36M |
| William Bee Ririe Hospital | Eureka, NV | $237K |
| Village Caregiving, LLC | Barboursville, WV | $153K |
| Rolling Hills Eye PLLC | Pullman, WA | $6K |
| Smart & Gibbs | Lehi, UT | $4K |
| William Bee Ririe Hospital | Crescent Valley, NV | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.